Vinorelbine
Childhood Mixed Glioma
National Cancer Institute (NCI)Phase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Childhood Mixed Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 1/2 | B |
Veliparib National Cancer Institute (NCI) | Phase 1/2 | B |
FILGRASTIM Roswell Park Cancer Institute | Phase 1 | CCC |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 1 | CCC |
Bortezomib National Cancer Institute (NCI) | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Vinorelbine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →